Dermata Therapeutics shares surge 19.09% intraday after closing $12.4M private placement to fund OTC acne kit launch and R&D.

Dermata Therapeutics surged 19.09% intraday after announcing the closing of a $12.4 million private placement, including $4.1 million upfront and up to $8.3 million in additional proceeds from warrants. The at-the-market offering, led by H.C. Wainwright & Co., included participation from company insiders and provided funding for the development and launch of its OTC acne kit, strategic acquisitions, and corporate initiatives. The transaction also involved warrant amendments to align terms with the new financing, enhancing investor flexibility. The capital raise signals progress toward the company’s 2026 acne kit launch and strengthens its position in dermatological solutions, likely driving investor optimism.